The company’s cross-disciplinary team lead by a Triple-Dr, Berenika Maciejewicz, applies bioengineering and AI towards human lifespan and healthspan extension.

Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one ...

Cantai launched in 2023 with a $3 million seed round. The company has raised $6.55 million to date at an undisclosed valuation, according to PitchBook. It develops drug candidates with special ...

In an interview with BioPharma Dive, the veteran biotech CEO said there remains a “significant opportunity” for young ...

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Massachusetts biotech working ...

The Drug Information Association (DIA) today announced the launch of DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its ...

An illustration of a protein created by Accipiter Bio that has two active sites, shown in light and darker green, that can simultaneously bind two targets. (Accipiter Bio Image) A Seattle biotech ...

That wasn't always Ehrhardt's focus. When he and co-founders Sandeep Singh and Nikki Arora Singh launched the company in 2023, the responsibilities of each team member were broad and varied. "In the ...

OpenAI is expanding its efforts to contain emerging risks posed by artificial intelligence, backing a new biotech spinoff aimed at stopping malicious actors from using advanced models to create ...

After months of searching for a suitable chief executive, local biotechnology startup Fate Therapeutics has found its match in Southern California and will move its headquarters there. The ...